MedTrace Logo

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial

NCT05882305 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-10-30

No results posted yet for this study

Summary

The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the range of effective dose.

Conditions

  • EBV-associated Lymphomas

Interventions

BIOLOGICAL

Autologous monocyte-derived DCs pulsed withEBV-associated antigen

Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.

Sponsors & Collaborators

  • Kousai Bio Co., Ltd.

    lead OTHER

Principal Investigators

  • Yang Jianmin · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-10
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05882305 on ClinicalTrials.gov